By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35



Company News
Celyad Announces New Agreements With Celdara Medical And Dartmouth College 8/4/2017 8:05:15 AM
BioLife Solutions, Inc. (BLFS.OB) Executes Supply Agreement With Celyad For CryoStor Use In Natural Killer Receptor Based T-Cell (NKR-T) Platform Targeting Solid Tumors And Blood Cancers 7/31/2017 8:29:43 AM
Celyad Announces Initiation Of The SHRINK Trial 7/20/2017 1:09:35 PM
Celyad Publishes Additional Pre-Clinical Data In Support Of THINK Trial 6/21/2017 8:24:29 AM
Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial 6/19/2017 10:49:51 AM
Celyad Obtains Additional US Patent For Cancer Treatment Based On TCR-Deficient Allogeneic CAR-T Cells 5/30/2017 9:59:51 AM
Celyad Announces First Quarter 2017 Business Update 5/19/2017 11:34:19 AM
Celyad Announces First Quarter 2017 Business Update 5/19/2017 8:02:50 AM
FDA Grants Fast Track Designation For Celyad’s Ischemic Heart Failure Therapy, C-Cure 5/11/2017 11:56:02 AM
Celyad Grants To Novartis AG (NVS) A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents 5/2/2017 11:00:22 AM